BMS-986012

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Extensive-stage Small Cell Lung CancerSmall Cell Lung Cancer

Phase 1

Trial of BMS-986012 in Combination With Platinum and Etoposide

CompletedNCT02815592

Bristol-Myers SquibbSmall Cell Lung Cancer

Start: 2016-11-28End: 2024-08-06Updated: 2024-09-04

Study of BMS-986012 in Subjects With Small Cell Lung Caner

CompletedNCT02949895

Bristol-Myers SquibbSmall Cell Lung Cancer

Start: 2016-11-29End: 2017-08-29Updated: 2019-08-12

Phase 2

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Active, not recruitingNCT04702880

Bristol-Myers SquibbExtensive-stage Small Cell Lung Cancer

Start: 2021-03-17End: 2025-12-31Target: 120Updated: 2025-10-08

Related Papers

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

JTO Clinical and Research Reports2022-08-2716 citations

Abstract 2479: Preclinical assessment of imaging agents for identification of fucosyl-GM1 expression <i>in vivo</i>

Cancer Research2022-06-15